Beta Drugs Ltd Q2 FY2025 Concall Summary

Key Takeaways

• Strong quarter, margin recovery: Revenue grew 28% YoY to INR180.3 crores, while EBITDA margin expanded to 22.36% from 20.75% last year, driven by lower platinum raw material costs and a deliberate shift toward more profitable products.
• Export engine is the growth story: International revenue surged 141% YoY (from a small base), and management expects ~50% export growth for the next 3–4 years, fueled by new registrations and the ZAZIBONA certification opening West Africa.
• Derma is burning cash but gaining traction: The segment posted negative EBITDA of INR1.3 crores on INR6.4 crores in H1 sales, but monthly revenue has crossed INR1 crore and the prescriber base expanded from 700 to 1,100 since April.
• Regulatory catalysts are stacked for H2: An EU-GMP audit is expected within 4 months, a COFEPRIS (Mexico) audit by January, and an Italian cosmetology product registration in a couple of months, each unlocking new markets.
• What to watch next quarter: Whether the EU-GMP inspection materializes on schedule, the pace of CDMO growth recovery from a flat H1, and if Derma can narrow its losses as the prescriber base scales toward 1,400 by year-end.

Export & Regulatory Pathway

• ZAZIBONA unlocks regional scale: The certification enables dossier filings across four West African countries including South Africa, with filings already underway and more registrations expected over the next couple of years.
• Registrations are the leading indicator: New approvals received mainly from LATAM and Asian markets, plus 6 COPPs received, are directly boosting sales now and create a pipeline for sustained export momentum.
• EU and Mexico audits are the next gates: An application for EU-GMP inspection has been filed across three countries, with one country already inviting inspection before March; the Beta facility audit is expected within 4 months. A COFEPRIS audit is expected by January.
• US entry is a medium-term plan: Management intends to enter the US market in 2–2.5 years, sequencing after the EU audit and dossier filings, then beginning product development and DMF preparation from the upcoming R&D facility.

Rahul Batra: "We expect around 50% growth on the export business for coming 3 years to 4 years down the line."

Margin & Product Mix Shift

• Platinum price relief drove the recovery: Last year margins fell to ~18% because major sales were platinum-based and raw material prices had spiked. This year, platinum prices declined and the company actively restricted growth toward more profitable products.
• Derma is the margin drag: Excluding the Derma segment (INR1.3 crores negative EBITDA), overall EBITDA would have been ~24% instead of the reported 22.36%, meaning the core oncology business is already running at a healthier level.
• Export margins are structurally higher: Management guided export EBITDA margins in the 23% to 26% range, so as the export mix grows, consolidated margins should benefit.
• Other expenses rose in line with sales: The increase includes selling expenses and one-time costs for trade shows (CPHI Milan, Arab Health Dubai), but the percentage of sales did not increase.

Rahul Batra: "This year the platin prices have gone down and also we have restricted our growth towards the more profitable products rather concentrating ourselves on the platin side."

Derma & Cosmetology Build-Out

• The unit economics are still negative but improving: H1 sales of INR6.4 crores with negative EBITDA of INR1.3 crores reflect the investment phase, but monthly revenue has crossed INR1 crore and momentum has built since April.
• Prescriber base is the key metric: The count has grown from 700 to 1,100, with a target of 1,300–1,400 by year-end and over 2,200 next financial year, which management expects will drive the topline toward breakeven.
• Italian partnership adds a premium layer: A tie-up with a European company from Italy will bring unique cosmetology products to the Indian market; registration is expected in a couple of months, with at least five more drugs planned for launch.

CDMO & API Strategy

• CDMO was flat in H1 but partners are retained: The segment did INR72.7 crores with only 2–5% growth, but no partners were lost and management expects better sales in the second half, guiding 7–10% full-year growth.
• API is being rebuilt for regulated markets: The three-part strategy is to upgrade the facility to state-of-the-art, prepare strong DMFs for regulated markets, and hire a dedicated person to handle API international business. Three new molecules have been filed for approval, expected next financial year.
• Intermediate facility adds backward integration: A new intermediate plant (INR15–20 crores initial investment) will support the API plant for EU regulations and fall under the EU-GMP scope; some Indian cytotoxic API companies have already shown interest in buying intermediates.

Rahul Batra: "As you know, government of India is pushing a lot towards Make in India right now."

Pipeline: NDDS, Biosimilars & New Molecules

• NDDS is creating new markets, not just taking share: The megestrol acetate suspension launch expanded the total market beyond the existing tablet segment, and management expects a similar effect from two more NDDS launching next year with a combined addressable market of ~INR70 crores.
• Three more NDDS are in the DCGI queue: Product development is complete, approvals are expected in 12–15 months, and launches are slated for FY26–27.
• Biosimilars and biologics are the third growth driver: Management is trying to tie up on an exclusivity basis to launch biosimilars in India, and has shortlisted hormonal therapy products (Apalutamide, Degarelix, darolutamide, Exemestane) for launch in the next two years.
• R&D spend is set to rise: A new combined API and formulation R&D center (INR10–15 crores capex) will push R&D expense from 2–3% of sales to 4–5% once operational.

Ashutosh Shukla: "The next growth driver will be supportive care products wherein as of now our presence is very less and the third growth driver for us is biologics."

Balance Sheet & Fundraise

• INR117 crores raised from marquee healthcare investors: HealthQuad (backed by Quadria Capital, with LPs including Merck and J&J), Tanas Capital, and a generational capital fund participated, with the instrument structured as compulsory convertible debentures carrying a 0.65% monthly coupon and an 18-month conversion window.
• No further dilution expected near-term: Management stated no additional funds are needed until turnover reaches INR450–500 crores, a milestone expected probably by next year.
• Working capital is stable: Trade receivables days are holding in the 98–102 day range, and overall working capital days are consistent at 86.
• Capex is focused on regulatory readiness: Facility upgrades have been completed to support audits for Beta registrations in regulated countries, and the new intermediate and R&D facilities are the next capital allocation priorities.

Guidance & Commitments

Key Metrics